Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

NCT01042379 is registered in ClinicalTrials.gov with QuantumLeap Healthcare Collaborative as lead sponsor.

NCT NCT01042379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01042379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Lead sponsor
QuantumLeap Healthcare Collaborative
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2010
Completion date
December 31, 2031
Enrollment
5,000 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, breast cancer, breast neoplasms, breast tumors, early-stage breast cancer, her2-negative breast cancer, her2-positive breast cancer, hormone receptor negative tumor, hormone receptor positive tumor, locally advanced breast cancer, tnbc - triple-negative breast cancer